641 related articles for article (PubMed ID: 15809483)
1. Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.
Brix G; Lechel U; Glatting G; Ziegler SI; Münzing W; Müller SP; Beyer T
J Nucl Med; 2005 Apr; 46(4):608-13. PubMed ID: 15809483
[TBL] [Abstract][Full Text] [Related]
2. Technologist radiation exposure in routine clinical practice with 18F-FDG PET.
Guillet B; Quentin P; Waultier S; Bourrelly M; Pisano P; Mundler O
J Nucl Med Technol; 2005 Sep; 33(3):175-9. PubMed ID: 16145226
[TBL] [Abstract][Full Text] [Related]
3. Radiation exposure of patients and personnel from a PET/CT procedure with 18F-FDG.
Leide-Svegborn S
Radiat Prot Dosimetry; 2010; 139(1-3):208-13. PubMed ID: 20167792
[TBL] [Abstract][Full Text] [Related]
4. PET/CT and SPECT/CT dosimetry in children: the challenge to the pediatric imager.
Gelfand MJ; Lemen LC
Semin Nucl Med; 2007 Sep; 37(5):391-8. PubMed ID: 17707244
[TBL] [Abstract][Full Text] [Related]
5. Doses to nuclear technicians in a dedicated PET/CT centre utilising 18F fluorodeoxyglucose (FDG).
Seierstad T; Stranden E; Bjering K; Evensen M; Holt A; Michalsen HM; Wetteland O
Radiat Prot Dosimetry; 2007; 123(2):246-9. PubMed ID: 16987913
[TBL] [Abstract][Full Text] [Related]
6. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
[TBL] [Abstract][Full Text] [Related]
7. A Monte Carlo based method to estimate radiation dose from multidetector CT (MDCT): cylindrical and anthropomorphic phantoms.
DeMarco JJ; Cagnon CH; Cody DD; Stevens DM; McCollough CH; O'Daniel J; McNitt-Gray MF
Phys Med Biol; 2005 Sep; 50(17):3989-4004. PubMed ID: 16177525
[TBL] [Abstract][Full Text] [Related]
8. Operational radiation safety for PET-CT, SPECT-CT, and cyclotron facilities.
Zanzonico P; Dauer L; St Germain J
Health Phys; 2008 Nov; 95(5):554-70. PubMed ID: 18849690
[TBL] [Abstract][Full Text] [Related]
9. Weight-based, low-dose pediatric whole-body PET/CT protocols.
Alessio AM; Kinahan PE; Manchanda V; Ghioni V; Aldape L; Parisi MT
J Nucl Med; 2009 Oct; 50(10):1570-7. PubMed ID: 19793734
[TBL] [Abstract][Full Text] [Related]
10. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
[TBL] [Abstract][Full Text] [Related]
11. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
12. Early detection of cancer recurrence: 18F-FDG PET/CT can make a difference in diagnosis and patient care.
Israel O; Kuten A
J Nucl Med; 2007 Jan; 48 Suppl 1():28S-35S. PubMed ID: 17204718
[TBL] [Abstract][Full Text] [Related]
13. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
14. Monitoring cancer treatment with PET/CT: does it make a difference?
Weber WA; Figlin R
J Nucl Med; 2007 Jan; 48 Suppl 1():36S-44S. PubMed ID: 17204719
[TBL] [Abstract][Full Text] [Related]
15. Whole-body radiation dosimetry of 2-[18F]Fluoro-A-85380 in human PET imaging studies.
Obrzut SL; Koren AO; Mandelkern MA; Brody AL; Hoh CK; London ED
Nucl Med Biol; 2005 Nov; 32(8):869-74. PubMed ID: 16253812
[TBL] [Abstract][Full Text] [Related]
16. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
17. PET/CT: dose-escalated image fusion?
Brix G; Beyer T
Nuklearmedizin; 2005; 44 Suppl 1():S51-7. PubMed ID: 16395980
[TBL] [Abstract][Full Text] [Related]
18. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
19. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET/CT for staging of penile cancer.
Scher B; Seitz M; Reiser M; Hungerhuber E; Hahn K; Tiling R; Herzog P; Reiser M; Schneede P; Dresel S
J Nucl Med; 2005 Sep; 46(9):1460-5. PubMed ID: 16157528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
